Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | TPH1 | P17752 | 1/20 | 0.35 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165166 | 0.94 | TLR7 (0.42) | MAPTTP53TSHRADORA2BTLR7 | |
| SCHEMBL1333412 | 0.93 | TLR7 (0.41) | MAPTTP53TSHRADORA2BTLR7 | |
| SCHEMBL4182286 | 0.93 | MAPT (0.40) | MAPTTP53TSHRADORA2BTLR7 | |
| SCHEMBL4186574 | 0.92 | ADORA2A (0.35) | MAPTTP53TSHRADORA2BALDH1A1 | |
| SCHEMBL4172631 | 0.91 | ADORA2A (0.35) | MAPTTP53TSHRADORA2BALDH1A1 | |
| SCHEMBL4167578 | 0.91 | MAPT (0.40) | MAPTTP53TSHRADORA2BALDH1A1 | |
| SCHEMBL4183577 | 0.90 | TSHR (0.39) | MAPTTP53TSHRADORA2BTLR7 | |
| SCHEMBL4165128 | 0.87 | CHRNB2 (0.36) | MAPTTP53TSHRADORA2BTLR7 | |
| SCHEMBL4180241 | 0.86 | CHRNB2 (0.36) | MAPTTP53TSHRADORA2BTLR7 | |
| SCHEMBL4189331 | 0.86 | ADORA2A (0.35) | MAPTTP53TSHRADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1636230-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110379-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | HRH3, HRH1, HRH2 | MAPT 4646/4885TP53 3667/4885TSHR 1275/4885 |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA3, ADORA2A | MAPT 4543/4885TP53 3069/4885TSHR 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.